The U.S. Food and Drug Administration granted fast track status for the development of AstraZeneca’s diabetes drug Farxiga to prevent heart and kidney failure in patients with chronic kidney disease.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
A Chicago-based arbitration panel ruled in favor of Eli Lilly and Company in a claim filed by Adocia S.A. over the companies’ prior collaboration on a rapid-acting insulin.
Denmark’s Novo Nordisk filed a lawsuit in a Delaware district court against generic drugmaker Mylan.
Older adults who cut back on the amount of vegetable protein in their diets may be more likely to experience age-related health problems than their peers who increase the amount of plant protein they eat, a Spanish study suggests.
AstraZeneca made strides toward the company’s goal of adding heart failure to the conditions that can be treated by Farxiga, putting the diabetes drug ahead of a rival medicine from Eli Lilly.
The only liver disease becoming more widespread in the U.S. is one driven by obesity and diabetes – NAFLD – even as other liver disorder types linked to drinking or hepatitis become less common.
Innovations in diabetes care go beyond new therapeutic classes. Pharmaceutical companies are continuing to invest in new technology to help improve diabetes treatment and patient adherence with progress ranging from artificial pancreases to smart insulin pens and pumps.
Shares of Texas-based Lexicon Pharmaceuticals shot up after the company announced positive 52-week cardiorenal data from a pooled analysis of the type 1 diabetes trials Tandem1 and Tandem2.
Novo Nordisk’s sales forecast for 2019 was raised due to growing demand for obesity products and a new injectable treatment for diabetes, which is now the company’s growth engine as insulin sales decline.
Eli Lilly and Co. beat analysts’ estimates for second-quarter 2019 profit and raised the company’s full-year earnings forecast, as higher sales of the diabetes drugs Trulicity and Basaglar offset competition for the erectile dysfunction treatment Cialis.